(NASDAQ: CAPR) Capricor Therapeutics's forecast annual revenue growth rate of 7.75% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 59.26%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.23%.
Capricor Therapeutics's revenue in 2024 is $25,178,066.On average, 1 Wall Street analysts forecast CAPR's revenue for 2024 to be $891,750,543, with the lowest CAPR revenue forecast at $891,750,543, and the highest CAPR revenue forecast at $891,750,543. On average, 1 Wall Street analysts forecast CAPR's revenue for 2025 to be $706,492,508, with the lowest CAPR revenue forecast at $706,492,508, and the highest CAPR revenue forecast at $706,492,508.
In 2026, CAPR is forecast to generate $1,155,507,746 in revenue, with the lowest revenue forecast at $1,155,507,746 and the highest revenue forecast at $1,155,507,746.